Thus, a better understanding of the mechanisms controlling signaling pathways may enable the identification of new therapeutic targets for the prevention of aberrant NF-κB, MAPK, and PKC-θ cascade activation in human SIRS and sepsis. This evidence concerns the gene NFKB1 and systemic inflammatory response syndrome.